Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence
Immunocompromising conditions increase the risk of invasive pneumococcal disease (IPD). Vaccine uptake in patients with these conditions may be low in part because of concerns about decreased immunogenicity and safety in these high-risk groups. We conducted a literature search to identify publicatio...
Saved in:
Main Authors: | Erica Chilson (Author), Daniel A. Scott (Author), Beate Schmoele-Thoma (Author), Wendy Watson (Author), Mary M. Moran (Author), Raul Isturiz (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2020-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
by: Jeffrey Vietri, et al.
Published: (2020) -
Adult indication 13-valent pneumococcal conjugate vaccine clinical development overview: formulation, safety, immunogenicity (dosing and sequence), coadministration, and efficacy
by: Mark A. Fletcher, et al.
Published: (2024) -
Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations
by: Christine Juergens, et al.
Published: (2018) -
Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
by: Beate Schmoele-Thoma, et al.
Published: (2019) -
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial
by: Bhagirath B. Solanki, et al.
Published: (2017)